X
XENE
vs
S&P 500
S&P 500
Over the past 12 months, XENE has underperformed S&P 500, delivering a return of +7% compared to the S&P 500's +12% growth.
Stocks Performance
XENE vs S&P 500
Performance Gap
XENE vs S&P 500
Performance By Year
XENE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Xenon Pharmaceuticals Inc
Glance View
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company spotlighted in the arena of precision medicine, with a strategic emphasis on neurological disorders. The company finds its roots in the ethos of innovation, aiming to transform the landscape of treatment through the development of novel therapeutics. At the heart of its operations is a robust platform driven by genetic insights, which allows the company to unearth underlying neurological pathways, thereby targeting diseases that truly lack effective treatment options. Xenon leverages its deep expertise in ion channel biology—vastly important in the function of the nervous system—to design small molecule therapies, positioning itself as a pioneer in addressing complex cerebral disorders such as epilepsy. A key aspect of how Xenon Pharmaceuticals generates revenue is through a dual approach: self-initiated proprietary product development and strategic collaborations with established pharmaceutical giants. Its revenue model is largely propelled by both developmental milestone payments and potential royalties from these alliances. This includes partnerships that allow Xenon to share its innovative platform while receiving financial backing and resources, ensuring the infrastructural strength needed to sustain its clinical programs. By maintaining a pipeline that promises targeted, personalized treatments, Xenon aims not only to meet clinical milestones but to also carve out significant market share within the neuroscience domain, paving its path to profitability and industry impact.
